Clinical analysis of Rituximab-and Sintilimab-induced interstitial lung disease in patients with malignant tumors
HOU Lanfen
LI Wenjing
WANG Yongmin
LI Jing
ZHENG Yunxia
LI Li
ZHANG Baojin
XUE Qian
Abstract：Objective Objective To explore the clinical characteristics of Rituximab-induced interstitial lung disease(RILD)and Sintilimab-induced immune checkpoint inhibitor interstitial pneumonia(CIP)in patients with malignant tumors.Methods A retrospective analysis was conducted on the clinical data of 12 patients with malignant tumors who developed RILD or CIP after chemotherapy from January 2010 to December 2024.Results The occurrence time of RILD and CIP in this group was from the 3rd to the 6th cycle of treatment,with a median occurrence time of the 4th cycle.All 12 patients presented with typical chest CT manifestations.Among them,2 patients had no obvious symptoms,and the remaining 10 patients had typical clinical symptoms.Both of the two patients classified as grade 1 were RILD.There were 9 patients with grade 2(3 patients had RILD and 6 patients had CIP),1 patient with grade 3 had CIP,and no patient with grade 4 were observed.Two patients with grade 1 CIP were only closely observed.Nine patients with grade 2 to 3 RILD and CIP were treated with Glucocorticoids combined with Moxifloxacin.One patient with grade 3 RILD was treated with Cephalosporin Antibiotics combined with Glucocorticoids and Yangyin Qingfei pills.The therapeutic effects were satisfactory.Conclusion Patients with malignant tumors should follow the treatment guidelines of the Chinese Society of Clinical Oncology(CSCO)for standardized medication.When RILD and CIP occur,clinicians and clinical pharmacists should cooperate closely,and monitor and use drugs rationally,which can significantly improve the cure rate of RILD and CIP.
Keywords：diffuse large B-cell lymphomaNK/T-cell lymphomacardia cancerinvasive breast cancerrituximabsintilimabinterstitial pneumoniaglucocorticoid
Publication Date：2025-09-28
Online Publishing Date：2025-10-17(First online date of this platform, not the publication date of the document)
Pages：6( 19-23,30 )